From the Clinical Pharmacology Unit, University of Cambridge, Addenbrooke’s Hospital (A.D.B., R.K.K., C.M.M., I.S.M., I.B.W.); the Department of Nephrology, Addenbrooke’s Hospital (D.R.W.J.); and GlaxoSmithKline Translational Medicine and Technology Group, GSK Clinical Research Unit, ACCI, Addenbrooke’s Hospital (J.B.), Cambridge, United Kingdom. (At 2004-04-13)
